Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age21-90
SponsorUniversity of Colorado, Denver

About this trial

RATIONALE: Studying samples of sputum and tissue in the laboratory from patients with dysplasia or cancer may help doctors identify and learn more about biomarkers related to cancer. It may also help the study of cancer in the future.

PURPOSE: This laboratory study is looking at biomarkers in patients with respiratory tract dysplasia or lung cancer, head and neck cancer, or aerodigestive tract cancer.

Eligibility criteria

Qualifiers

Diagnosis of extensive and severe dysplasia of the respiratory epithelium

Those without dysplasia of the respiratory epithelium

Recruited from the SPORE Tissue Procurement Screening Project or by private or academic physicians (for patients with moderate or severe dysplasia)

Survived 1 or more aerodigestive system carcinoma for ≥ 1 year

Disqualifiers

None

Trial design

Treatments tested in this trial

  • immunohistochemistry staining method
  • laboratory biomarker analysis
  • sputum cytology
  • biopsy

Treatment groups

No treatment groups listed

Sponsors and collaborators

University of Colorado, Denver

Lead sponsor

National Cancer Institute (NCI)

Collaborator